Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
culture-expanded adipose-derived regenerative cells
- Development stage
- Phase 2
- Lead developer
- Rigshospitalet
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraglandular
01
Overview
Culture-expanded adipose-derived regenerative cells (ceADRCs), also frequently referred to as culture-expanded adipose-derived mesenchymal stem cells (ceASCs), are an autologous cell therapy being developed by Rigshospitalet (Copenhagen University Hospital) for the treatment of radiation-induced xerostomia and hyposalivation. The therapy involves extracting a patient's own adipose tissue via liposuction, isolating the mesenchymal stem cells, and expanding them in a controlled laboratory environment to reach a therapeutic dose. These expanded cells are then injected directly into the submandibular salivary glands. The therapeutic effect is primarily mediated through paracrine signaling, where the cells secrete a variety of growth factors and cytokines that promote angiogenesis, reduce chronic inflammation, and mitigate fibrosis in the radiation-damaged glandular tissue, thereby aiming to restore salivary gland function and improve the patient's quality of life.
- Other names
- culture-expanded adipose-derived mesenchymal stem cellsadipose-derived mesenchymal stem cellsadipose-derived stromal cellsautologous adipose-derived mesenchymal stem cellsceASC
Beyond the preview
Go deeper on culture-expanded adipose-derived regenerative cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on culture-expanded adipose-derived regenerative cells.